Trial Profile
Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenstrom, B-CLL and Other Indolent B-Cell Lymphomas.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Pentostatin (Primary) ; Cyclophosphamide; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms PERLL
- 30 Jun 2009 New trial record